Bionomics

#9997

Rank

$5.84M

Marketcap

Australia

Country

Leadership team

Dr. Errol B. De Souza Ph.D. (Exec. Chairman)

Mr. Adrian Hinton BEC, F.C.A. (Acting Chief Financial Officer)

Mr. Connor Bernstein M.Sc. (VP of Strategy & Corp. Devel.)

Products/ Services

Biotechnology, Health Diagnostics, Medical

Headquarters

Thebarton, South Australia, Australia

Established

1999

Company Registration

SEC CIK number: 0001191070

Traded as

BNOX

Social Media

URL

https://www.bionomics.com.au

Overview

Location

Recognition and Award

References

Summary

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

History

Bionomics was founded in 1991, originally focusing on the development of new treatments in the fields of oncology and women's reproductive health. The company has since expanded to include drug discovery for neurodegenerative and inflammatory disorders. Over the past two decades, Bionomics has developed six compounds that are progressing through clinical development in the US and Europe.

Mission

Our mission is to develop and deliver innovative therapies to improve the lives of patients with diseases or conditions with unmet medical needs.

Vision

Our vision is to be a leader in the development of innovative therapies and provide excellence in delivering patient care.

Key Team

Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D. (Consultant Chief Medical Officer of Clinical Neuroscience)

Ms. Suzanne Irwin B.Com., FCIS (Company Sec.)

Recognition and Awards

Bionomics has received numerous awards for its work in the development of potentially life-changing therapeutics, including the Australian Institute of Pharmaceutical Science and Technology's Valued Supplier Awards, the European Society of Clinical Pharmacy Author's Award and the New England BioLabs Prize for Outstanding Scientific Achievement.